Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model

In order to investigate the capability of two chelators deferasirox (DFX or ICL670) and deferiprone (L 1 ) in removing lead from the body, the present research was performed. Two does levels of 40 and 80 mg/kg body weight of lead (II) chloride was given to rats as biological model for 45 days. After...

Full description

Saved in:
Bibliographic Details
Published in:Biometals Vol. 27; no. 1; pp. 89 - 95
Main Authors: Balooch, F. Dahooee, Fatemi, S. J., Iranmanesh, M.
Format: Journal Article
Language:English
Published: Dordrecht Springer Netherlands 01-02-2014
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In order to investigate the capability of two chelators deferasirox (DFX or ICL670) and deferiprone (L 1 ) in removing lead from the body, the present research was performed. Two does levels of 40 and 80 mg/kg body weight of lead (II) chloride was given to rats as biological model for 45 days. After 45 days, some toxicity symptoms were observed in rats such as loss of hair and weight, appearance of red dots around eyes, weakness and irritability. After lead application, chelation therapy with DFX and L 1 as mono and combined (DFX, L 1 and DFX + L 1 ) was done for 10 days. After chelation therapy, lead level in different tissues reduced. The combined chelation therapy results showed that these chelators are able to remove lead from the body and toxicity symptoms decreased. The combined therapy results (DFX + L1) show higher efficacy and lower toxicity compared to single therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0966-0844
1572-8773
DOI:10.1007/s10534-013-9689-0